pembrolizumab
Keytruda Receives Traditional Approval for Some Patients With HER2-Positive Gastric or GEJ Adenocarcinoma
The FDA has granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and ...
MARCH 20, 2025
10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of ...
NOVEMBER 27, 2024
First-Line Pembrolizumab Improves Survival in Triple-Negative Breast Cancer
Following publication of an interim analysis in 2020, the data from the phase 3 KEYNOTE-522 study (N Engl J Med ...
NOVEMBER 25, 2024
Overall Survival Benefit Supports New Standard in High-Risk, Locally Advanced Cervical Cancer
In patients with high risk, locally advanced cervical cancer, previously reported data demonstrated an advantage ...
OCTOBER 10, 2024
FDA Approves Keytruda With Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
The FDA has approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum-based chemotherapy as first-line ...
SEPTEMBER 18, 2024
Immunotherapy Before Surgery for Stage III Melanoma Significantly Improves Outcomes
After resection of stage III melanoma, adjuvant immunotherapy has previously been associated with a reduction in ...
JUNE 24, 2024
FDA Approves Keytruda With Chemo for Primary Advanced or Recurrent Endometrial Carcinoma
The FDA has approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent ...
JUNE 18, 2024
Survival Benefit Seen With Adjuvant Therapy in Patients With ccRCC
Adjuvant pembrolizumab (Keytruda, Merck) significantly improved overall survival in patients with clear cell renal ...
FEBRUARY 14, 2024
Keytruda With Chemoradiotherapy Approved for FIGO 2014 Stage III-IVA Cervical Cancer
The FDA approved pembrolizumab (Keytruda, Merck) with chemoradiotherapy (CRT) for patients with FIGO 2014 stage III ...
JANUARY 17, 2024
FDA Approves Padcev with Keytruda for Locally Advanced or Metastatic Urothelial Cancer
The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, ...
DECEMBER 17, 2023
FDA Approves Keytruda With Chemotherapy for HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
The FDA approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for ...
NOVEMBER 16, 2023
FDA Amends Keytruda’s Gastric Cancer Indication
On Nov. 7, 2023, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab-, ...
NOVEMBER 10, 2023